Study identifier:NIS-CBA-CRE-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina
hypercholesterolaemia
-
No
-
All
800
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2014 by AstraZeneca
AstraZeneca
-
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina
Location
Location
Banja Luka, Bosnia And Herzegovina
Location
Bijeljina, Bosnia And Herzegovina
Location
Doboj, Bosnia And Herzegovina
Location
Gradiška, Bosnia And Herzegovina
Location
Kakanj, Bosnia And Herzegovina
Location
Maglaj, Bosnia And Herzegovina
Location
Prijedor, Bosnia And Herzegovina
Location
Sarajevo, Bosnia And Herzegovina
Arms | Assigned Interventions |
---|---|
Patients with hypercholesterolaemia | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.